Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
The present invention relates to pharmaceutical compositions comprising a sulfonamide-including compound in combination with an angiogenesis inhibitor.
1. A pharmaceutical composition comprising a sulfonamide-including compound in combination with a VEGF receptor kinase inhibitor,
wherein the sulfonamide-including compound is N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide
or a pharmacologically acceptable salt thereof or a solvate thereof, and
wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclopropyl-aminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof or a solvate thereof.
2. The pharmaceutical composition according to claim 1 , wherein the VEGF receptor kinase inhibitor is a methanesulfonate salt of 4-(3-chloro-4-(cyclopropylamino-carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.
3. The pharmaceutical composition according to any one of claims 1 and 2 , which is a pharmaceutical composition for cancer treatment.
4. The pharmaceutical composition according to any one of claims 1 and 2 , which is a pharmaceutical composition for angiogenesis inhibition.
5. A method for treating cancer and/or a method for inhibiting angiogenesis, which comprises administering a sulfonamide-including compound and a VEGF receptor kinase inhibitor to a patient,
wherein the sulfonamide-including compound is N-(3-cyano-4-methyl-1H-indol-7-yl)-3-cyanobenzenesulfonamide, or a pharmacologically acceptable salt thereof or a solvate thereof, and
wherein the VEGF receptor kinase inhibitor is 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide, or a pharmacologically acceptable salt thereof or a solvate thereof.
6. The method according to claim 5 , wherein the VEGF receptor kinase inhibitor is a methanesulfonate salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide.